186448-73-7

Upstream product

• 157837-33-7 tert-Butyl-((R)-2-[1,3]dithian-2-yl-propoxy)-diphenyl-silane 
• 131233-29-9 (R)-2-(1,3-dithian-2-yl)-1-propanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 186448-88-4 2,2-Dimethyl-propionic acid (E)-(2R,5R)-2-(tert-butyl-dimethyl-silanyloxy)-5-{2-[(2S,3R)-2-(4-methoxy-benzyloxy)-4-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-3-methyl-butyl]-[1,3]dithian-2-yl}-3-methyl-hex-3-enyl ester 
• 186448-87-3 2,2-Dimethyl-propionic acid (E)-(2R,5R)-2-hydroxy-5-{2-[(2S,3R)-2-(4-methoxy-benzyloxy)-4-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-3-methyl-butyl]-[1,3]dithian-2-yl}-3-methyl-hex-3-enyl ester 
• 164714-15-2 (E)-(2R,5R)-2-(tert-Butyl-dimethyl-silanyloxy)-5-{2-[(2S,3R)-2-(4-methoxy-benzyloxy)-4-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-3-methyl-butyl]-[1,3]dithian-2-yl}-3-methyl-hex-3-en-1-ol 
• 164714-14-1 {(1R,2R,4S)-4-[(2R,3S)-4-{2-[(E)-(R)-3-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-1-methyl-but-2-enyl]-[1,3]dithian-2-yl}-3-(4-methoxy-benzyloxy)-2-methyl-butyl]-2-methoxy-cyclohexyloxy}-triisopropyl-silane 
• 186448-80-6 (E)-(2R,5R)-5-{2-[(2S,3R)-2-(4-Methoxy-benzyloxy)-4-((1S,3R,4R)-3-methoxy-4-triisopropylsilanyloxy-cyclohexyl)-3-methyl-butyl]-[1,3]dithian-2-yl}-3-methyl-hex-3-ene-1,2-diol 
• 186448-78-2 (R)-2-Benzenesulfonyl-1-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-3-[1,3]dithian-2-yl-butan-1-one 
• 186448-77-1 (R)-2-Benzenesulfonyl-1-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-3-[1,3]dithian-2-yl-butan-1-ol 
• 157837-34-8 2-((R)-2-Benzenesulfonyl-1-methyl-ethyl)-[1,3]dithiane 

Relevant academic research and scientific papers

Rapamycin synthetic studies. 1. Construction of the C(27)-C(42) subunit

A convergent synthetic approach to the C(27)-C(42) fragment of the immunosuppressive macrocycle rapamycin is described.

A unified total synthesis of the immunomodulators (-)-rapamycin and (-)-27-demethoxyrapamycin: Construction of the C(21-42) perimeters

A total synthesis of the potent, naturally occurring immunomodulators (-)-rapamycin (1) and (-)-27-demethoxyrapamycin (2) has been achieved via a unified, highly convergent synthetic strategy. Both targets were elaborated from common building blocks A-E,